Joint Dysfunctionality Alleviation along with Systemic Inflammation Reduction Following Arthrocen Treatment in Patients with Knee Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Clinical Trial

このレポートは 本レポートは によって検証されています。

研究概要

119 patients with mild/moderate knee osteoarthritis were randomized to receive Arthrocen capsules, an avocado/soy supplement, or a placebo. Outcomes of interest included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Short-Form 20 (SF-20) quality of life questionnaire, Lequesne scores, pain on a Visual Analog Scale, joint tenderness, patella crepitus, joint shrug sign, and inflammatory markers (tumour necrosis factor-alpha [TNF-a]; interleukin [IL] 17, IL 10, IL 4). Outcomes were assessed after 3 months of follow-up, and at 3 and 6 months of follow-up for inflammatory markers. Arthrocen reduced joint tenderness and lowered all inflammatory marker levels vs. placebo.